Phimosis: A rare complication of immunotherapy with durvalumab

Adjuvant nivolumab is the first immunotherapy to demonstrate a benefit in the treatment of high-risk muscle-invasive urothelial carcinoma - Onco Americas

5167 PDFs Review articles in FORESKIN

Luis Guillermo LLORENTE PETERS, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, INNSZ, Immunology & Rheumatology

JCM, Free Full-Text

Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature

Immunotherapy for Unresectable HCC, For HCPs

Enfortumab Vedotin Approved for Recurrent Bladder Cancer - NCI

673662 PDFs Review articles in DOSING

Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis - European Journal of Cancer